Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Clinical pharmacology of novel selective COX-2 inhibitors.

Tacconelli S, Capone ML, Patrignani P.

Curr Pharm Des. 2004;10(6):589-601. Review.

PMID:
14965322
2.

Clinical pharmacology of selective COX-2 inhibitors.

Capone ML, Tacconelli S, Sciulli MG, Patrignani P.

Int J Immunopathol Pharmacol. 2003 May-Aug;16(2 Suppl):49-58. Review.

PMID:
14552704
3.

Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor.

Patrignani P, Capone ML, Tacconelli S.

Expert Opin Pharmacother. 2003 Feb;4(2):265-84. Review.

PMID:
12562317
4.

New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.

Hochberg MC.

Semin Arthritis Rheum. 2002 Dec;32(3 Suppl 1):4-14. Review.

PMID:
12528069
5.

An evidence-based evaluation of the gastrointestinal safety of coxibs.

Bombardier C.

Am J Cardiol. 2002 Mar 21;89(6A):3D-9D. Review.

PMID:
11909555
6.

What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.

Hochberg MC.

Clin Exp Rheumatol. 2001 Nov-Dec;19(6 Suppl 25):S15-22. Review.

PMID:
11695246
7.

COX-2-selective inhibitors in the treatment of arthritis.

Schnitzer TJ, Hochberg MC.

Cleve Clin J Med. 2002;69 Suppl 1:SI20-30. Review.

PMID:
12086290
9.

Outcomes studies of the gastrointestinal safety of cyclooxygenase-2 inhibitors.

Scheiman JM.

Cleve Clin J Med. 2002;69 Suppl 1:SI40-6. Review.

PMID:
12086292
10.

COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective.

Hochberg MC.

Curr Top Med Chem. 2005;5(5):443-8. Review.

PMID:
15974939
11.

Current perspective on the cardiovascular effects of coxibs.

Konstam MA, Weir MR.

Cleve Clin J Med. 2002;69 Suppl 1:SI47-52. Review.

PMID:
12086293
12.

Role of COX-2 inhibitors in the evolution of acute pain management.

Sinatra R.

J Pain Symptom Manage. 2002 Jul;24(1 Suppl):S18-27. Review.

PMID:
12204484
13.

Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis.

Goldenberg MM.

Clin Ther. 1999 Sep;21(9):1497-513; discussion 1427-8. Review.

PMID:
10509845
14.

Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis.

Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ.

Arch Intern Med. 2000 Oct 23;160(19):2998-3003.

PMID:
11041909
15.

Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitor.

Bannwarth B, Berenbaum F.

Expert Opin Investig Drugs. 2005 Apr;14(4):521-33. Review.

PMID:
15882125
16.

[Coxibs: highly selective cyclooxygenase-2 inhibitors. Part II. Side effects].

Burdan F, Korobowicz A.

Pol Merkur Lekarski. 2003 Apr;14(82):352-5. Review. Polish.

PMID:
12868201
17.

Gastroduodenal safety of cyclooxygenase-2 inhibitors.

Scheiman JM.

Curr Pharm Des. 2003;9(27):2197-206. Review.

PMID:
14529400
18.

Cox-2 inhibitors: today and tomorrow.

McMurray RW, Hardy KJ.

Am J Med Sci. 2002 Apr;323(4):181-9. Review.

PMID:
12003372
19.

Etoricoxib.

Cochrane DJ, Jarvis B, Keating GM.

Drugs. 2002;62(18):2637-51; discussion 2652-3. Review.

PMID:
12466002
20.

Dual acting anti-inflammatory drugs: a reappraisal.

Bertolini A, Ottani A, Sandrini M.

Pharmacol Res. 2001 Dec;44(6):437-50. Review.

PMID:
11735348

Supplemental Content

Support Center